Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvectis Pharma, Inc. (NASDAQ: NVCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Nuvectis files reports with the U.S. Securities and Exchange Commission, including Form 8-K current reports that describe material events such as quarterly financial results, corporate updates and board appointments.
In recent Form 8-K filings, Nuvectis has reported the release of press statements covering second and third quarter financial results, business highlights and progress in its oncology pipeline. These filings reference the company’s lead program NXP900, an oral small molecule inhibitor of the SRC Family of Kinases including SRC and YES1, and its clinical development from Phase 1a dose escalation through initiation of a Phase 1b program. They also discuss NXP800, an oral small molecule GCN2 activator with reported anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer.
Filings confirm that Nuvectis’s common stock trades on the Nasdaq Capital Market under the symbol NVCT and that the company is classified as an emerging growth company. Additional 8-K reports document corporate governance developments, such as the appointment of a new member to the Board of Directors.
On Stock Titan, investors can use AI-powered tools to review Nuvectis’s SEC filings, with summaries that highlight key points from lengthy documents and clarify technical language. Real-time updates from EDGAR ensure that new 8-Ks, as well as other core filings like 10-K annual reports, 10-Q quarterly reports and Form 4 insider transaction disclosures when available, are quickly reflected. This structure helps users follow how clinical progress, financial performance and corporate decisions for NVCT are communicated through official regulatory channels.
Nuvectis Pharma has filed a shelf registration statement on Form S-3 allowing it to offer up to
The filing includes a dedicated at-the-market program to sell up to
Nuvectis Pharma, Inc. reported wider losses for 2025 as it advanced its lead oncology candidate NXP900 through early-stage clinical development. Cash and cash equivalents were $31.6 million as of December 31, 2025, up from $18.5 million a year earlier, mainly from a February 2025 public offering and use of its at-the-market facility.
The company’s net loss was $26.4 million for 2025 compared with $19.0 million in 2024, driven by higher research and development and general and administrative expenses, including $6.0 million of non-cash stock-based compensation and $2.4 million of one-time license milestone fees. Research and development expenses rose to $18.2 million, while general and administrative costs increased to $9.4 million.
Management highlighted progress in the NXP900 program, including an ongoing Phase 1b monotherapy study across selected tumor types and a combination study with osimertinib in EGFR-mutated NSCLC, with a lorlatinib combination in ALK-positive NSCLC pending initiation. The company believes its current cash can fund multiple NXP900 Phase 1b milestones and operations well into the second half of 2027.
Nuvectis Pharma, Inc. files its annual report, outlining a clinical-stage oncology business focused on precision medicines. The lead candidate, NXP900, is an oral SRC/YES1 kinase inhibitor licensed from the University of Edinburgh, with Phase 1a completed and a Phase 1b expansion under way in solid tumors.
The company has ceased clinical development of its other candidate, NXP800, after a Phase 1b study and is assessing possible next steps. As of December 31, 2025, accumulated losses reached $99.7 million, and the company expects continued losses as it advances development, relies on third-party manufacturers, and operates in a heavily regulated and competitive biopharmaceutical environment.
Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.
The restricted shares will vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to his continued service. After this grant, Shemesh beneficially owns 1,793,068 shares of Nuvectis common stock, including restricted shares, held directly.
Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.
After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.
Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.
The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.
Nuvectis Pharma vice president receives new equity grant. Nuvectis Pharma, Inc. reported that its Vice President of Finance, Michael J. Carson, was awarded 61,200 shares of restricted common stock on January 6, 2026. The grant was priced at $0 per share, reflecting a stock award rather than an open-market purchase.
The 61,200 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Carson’s continued service. After this grant, Mr. Carson beneficially owns a total of 200,118 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma (NVCT) reported an insider purchase by Chairman & CEO Ron Bentsur. On 11/05/2025, he bought 5,000 shares of common stock at $5.72 per share (transaction code P). Following the trade, his directly held beneficial ownership totals 3,525,924 shares.
The total includes 676,759 shares of restricted stock, as noted in the footnote. Bentsur is listed as Director, Chairman & CEO, and a 10% Owner, with the reported holdings shown as Direct (D).
Nuvectis Pharma (NVCT) director reported an open-market purchase of 13,000 shares on November 5, 2025 at a weighted average price of $5.79. After the transaction, the director beneficially owned 78,150 shares directly and 415 shares indirectly as custodian for a son. The filing notes the purchase was executed through multiple same-day trades within a price range of $5.77 to $5.81, consolidated as a single line item.